PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Fox, Kim
TI  - BEAUTIFUL Trial Fails to Meet Primary Endpoint
DP  - 2008 Nov 01
TA  - MD Conference Express
PG  - 12--13
VI  - 8
IP  - 6
4099  - http://mdc.sagepub.com/content/8/6/12.short
4100  - http://mdc.sagepub.com/content/8/6/12.full
AB  - Although the morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with coronary artery disease and left ventricULar dysfunction [BEAUTIFUL; NCT00143507] trial failed to meet its primary composite endpoint of cardiovascular death, admission to hospital for acute myocardial infarction (MI), and hospitalization for new-onset or worsening heart failure, it significantly reduced important secondary endpoints, such as hospitalization for fatal or non-fatal MI and coronary revascularization.